Equity Profile
Pre-Earnings Brief
Illumina Inc (ILMN) is a leading company in the health care sector, specializing in life sciences tools and services, particularly in genetic sequencing technology. Their innovations are crucial for advancements in personalized medicine, genomics, and diagnostics, making them a significant player in the growing field of biotechnology.
EPS
Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.
Revenue
Revenue figures will provide insight into overall sales performance and market demand for Illumina's products and services.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
8Q
EPS Beat Rate
100%
Avg EPS Surprise
+139.77%
Avg Stock Reaction
+0.69%
In the last quarter, Illumina reported an EPS of $1.35, surpassing expectations by 7.4%. However, the stock experienced a slight decline the following day, indicating mixed investor sentiment despite the positive earnings surprise.
Management Promises & Guidance
Analysts expect Illumina to report solid earnings this quarter, with a consensus EPS of $1.05 and revenue of $1.1 billion. The market is closely watching for any signs of growth in demand for their sequencing technologies.
Bull Case
If Illumina beats earnings expectations and provides strong guidance, it could signal robust demand for their products, leading to a positive market reaction.
Bear Case
Conversely, if the company fails to meet expectations or provides cautious guidance, it may raise concerns about slowing growth in a competitive market.
EPS
$1.05Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.
Revenue
$1.1BRevenue figures will provide insight into overall sales performance and market demand for Illumina's products and services.
Expectations
The print will turn on these two things.
Q1
Will Illumina's EPS exceed the consensus estimate of $1.05?
A beat on EPS would reinforce the company's growth story and could lead to a positive stock reaction.
Q2
What guidance will management provide regarding revenue growth for the upcoming quarters?
Management's outlook on revenue growth will be critical in assessing future demand and investor confidence.
Edge
Why consensus could be wrong
The consensus may underestimate Illumina's potential for revenue growth due to increasing demand for genomic sequencing in personalized medicine.
Supporting Evidence
Historical EPS surprises indicate strong operational performance, with a 100% beat rate over the last eight quarters.
The options market is pricing a larger move than historical averages, suggesting that traders expect significant volatility.
Recent insider buying activity, while small, indicates confidence in the company's future prospects.
Key Risk
If the company reports an EPS below $1.00, it could significantly undermine the bullish narrative.
Edge
Pre-commit to what would confirm each case.
This quarter's earnings will be pivotal in determining whether Illumina can sustain its growth trajectory in a competitive market.
Bull Confirmed If
An EPS of $1.10 or higher would confirm the bull case, indicating strong operational performance.
Bear Confirmed If
An EPS below $1.00 would confirm the bear case, raising concerns about demand and profitability.
Pre-Earnings Positioning
Implied Move
±5.1%
Historical Avg
±2.2%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.
Options are pricing ±5.0% while ILMN has averaged ±2.2% over the last 8 prints — setup is pricing rich.
30d HV
36.5%
Edge
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
n=30Fade rate: 7 of 20 (35%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 20 (65%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 5.8%, with a raw directional average of +2.2% (modestly positive historical bias).
Preparation
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Illumina beats expectations, history suggests a potential average one-day move of +0.69%, confirming strong demand.
In-Line / Cautious
If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future growth.
Miss
A miss could lead to a decline, with historical patterns suggesting an average one-day move of -3.7% following disappointing results.
Preparation
House & Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
1 buy·0 sells
Members
1
House only
Est. Notional
$1,001.00–$15,000.00
disclosed dollar ranges
Most Active Members
1 trade
Net buying
Recent Transactions
Traded Feb 10, 2026 · disclosed Mar 9, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.
Preparation
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ALEXANDRIA REAL ESTA REIT